Euclidean Capital LLC Denali Therapeutics Inc. Transaction History
Euclidean Capital LLC
- $779 Million
- Q1 2024
Shares
2 transactions
Others Institutions Holding DNLI
# of Institutions
217Shares Held
115MCall Options Held
142KPut Options Held
90.3K-
Baillie Gifford & CO14MShares$326 Million0.23% of portfolio
-
Black Rock Inc. New York, NY12.2MShares$283 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA11MShares$255 Million0.0% of portfolio
-
Wellington Management Group LLP Boston, MA8.27MShares$192 Million0.03% of portfolio
-
State Street Corp Boston, MA6.32MShares$147 Million0.01% of portfolio
About Denali Therapeutics Inc.
- Ticker DNLI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 134,174,000
- Market Cap $3.12B
- Description
- Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatm...